

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("**Inventiva**" or the "**Company**"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("**MASH**"), also known as non-alcoholic steatohepatitis ("**NASH**"), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2025:

- Cash: € 428,212.57
- Number of shares: 84,532

- Number of executions on buy side on semester: 1,642
- Number of executions on sell side on semester: 1,878
- Traded volume on buy side on semester: 267,584 shares for € 744,692.94
- Traded volume on sell side on semester: 296,504 shares for € 819,771.51

At the last half-year report as of December 31, 2024, the following resources were available in the liquidity account:

- Cash: € 349,630.55
- Number of shares: 113,452

- Number of executions on buy side on semester: 1,281
- Number of executions on sell side on semester: 1,366
- Traded volume on buy side on semester: 215,444 shares for € 477,452.69
- Traded volume on sell side on semester: 231,651 shares for € 538,913.35

When the contract was initially implemented, the following resources were included in the liquidity account:

- Cash: € 163,510.42
- Number of shares: 34,063

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1 886	322 578	1 074 534,26	1 610	276 147	938 985,90
01/02/2025	12	2,741	5,865.74	12	1,487	3,211.92
01/03/2025	3	485	1,033.05	9	1,320	2,811.60
01/06/2025	1	15	31.80	5	930	1,990.20
01/07/2025	-	-	-	10	1,750	3,780.00
01/08/2025	4	700	1,498.00	11	1,500	3,240.00
01/09/2025	8	1,050	2,236.50	5	864	1,857.60
01/10/2025	2	85	181.90	6	276	593.40
01/13/2025	7	915	1,939.80	8	732	1,566.48
01/14/2025	2	244	519.72	17	2,641	5,783.79
01/15/2025	9	1,266	2,772.54	4	750	1,657.50
01/16/2025	10	1,511	3,248.65	-	-	-
01/17/2025	2	229	485.48	2	500	1,080.00
01/20/2025	4	500	1,060.00	4	714	1,520.82
01/21/2025	2	500	1,065.00	6	786	1,682.04
01/22/2025	10	798	1,683.78	2	310	657.20
01/23/2025	-	-	-	75	14,338	34,267.82
01/24/2025	5	750	1,732.50	8	1,965	4,637.40
01/27/2025	14	2,791	6,223.93	12	1,000	2,270.00
01/28/2025	10	1,459	3,195.21	-	-	-
01/29/2025	13	2,000	4,320.00	6	1,000	2,180.00
01/30/2025	1	250	560.00	61	9,289	21,457.59
01/31/2025	1	41	95.12	11	1,567	3,713.79
02/03/2025	10	1,459	3,384.88	12	2,143	5,036.05
02/04/2025	5	500	1,155.00	11	1,000	2,330.00
02/05/2025	1	15	34.95	5	1,000	2,340.00
02/06/2025	6	1,026	2,380.32	5	252	589.68
02/07/2025	8	1,209	2,792.79	8	316	736.28
02/10/2025	12	2,000	4,580.00	1	1	2.33
02/11/2025	18	2,516	5,610.68	6	1,000	2,240.00
02/12/2025	5	500	1,110.00	9	1,323	2,963.52
02/13/2025	2	500	1,125.00	7	1,177	2,648.25
02/14/2025	-	-	-	12	1,751	3,992.28
02/17/2025	-	-	-	14	1,249	2,847.72
02/18/2025	-	-	-	25	3,931	9,159.23
02/19/2025	1	250	600.00	21	3,836	9,359.84
02/20/2025	1	250	605.00	7	583	1,428.35
02/21/2025	6	1,500	3,795.00	46	8,696	22,261.76
02/24/2025	4	750	2,062.50	52	9,521	26,373.17

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1 886	322 578	1 074 534,26	1 610	276 147	938 985,90
02/25/2025	3	669	1,879.89	34	5,500	15,620.00
02/26/2025	4	936	2,808.00	67	9,567	28,892.34
02/27/2025	15	2,750	8,415.00	41	6,752	21,066.24
02/28/2025	40	7,282	21,044.98	12	2,401	6,986.91
03/03/2025	56	8,280	23,018.40	26	3,895	10,944.95
03/04/2025	52	8,933	24,029.77	7	1,700	4,743.00
03/05/2025	19	3,389	8,879.18	15	2,751	7,290.15
03/06/2025	3	250	665.00	7	1,500	3,990.00
03/07/2025	4	500	1,320.00	45	6,478	17,749.72
03/10/2025	2	464	1,327.04	43	5,576	16,003.12
03/11/2025	30	5,595	15,777.90	4	700	2,023.00
03/12/2025	16	1,789	4,955.53	22	3,264	9,106.56
03/13/2025	37	4,652	12,699.96	3	674	1,853.50
03/14/2025	8	1,000	2,700.00	10	2,026	5,490.46
03/17/2025	3	85	234.60	18	3,500	9,695.00
03/18/2025	10	1,925	5,332.25	8	1,001	2,812.81
03/19/2025	6	1,068	2,926.32	10	1,789	4,919.75
03/20/2025	10	1,732	4,763.00	8	1,212	3,369.36
03/21/2025	16	1,250	3,437.50	5	790	2,180.40
03/24/2025	12	2,250	6,210.00	9	1,960	5,527.20
03/25/2025	5	1,001	2,722.72	7	1,300	3,575.00
03/26/2025	16	1,806	4,948.44	10	1,470	4,042.50
03/27/2025	7	1,043	2,836.96	8	1,530	4,238.10
03/28/2025	7	750	2,062.50	4	489	1,349.64
03/31/2025	14	2,740	7,425.40	17	2,761	7,565.14
04/01/2025	-	-	-	20	2,900	8,004.00
04/02/2025	11	2,500	6,925.00	13	2,001	5,602.80
04/03/2025	19	3,817	10,420.41	16	2,556	7,029.00
04/04/2025	27	5,294	13,976.16	-	-	-
04/07/2025	39	7,250	17,255.00	48	8,247	21,194.79
04/08/2025	6	950	2,565.00	13	2,255	6,156.15
04/09/2025	25	4,343	11,639.24	5	850	2,286.50
04/10/2025	9	2,157	5,737.62	24	3,455	9,293.95
04/11/2025	11	2,250	6,120.00	1	1	2.75
04/14/2025	3	500	1,355.00	51	7,185	20,118.00
04/15/2025	7	1,290	3,637.80	9	1,764	5,027.40
04/16/2025	9	856	2,422.48	10	1,595	4,545.75
04/17/2025	5	566	1,607.44	11	1,500	4,275.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1 886	322 578	1 074 534,26	1 610	276 147	938 985,90
04/22/2025	1	42	119.70	44	7,682	22,815.54
04/23/2025	11	2,000	6,080.00	40	6,381	20,163.96
04/24/2025	16	4,000	12,600.00	18	2,001	6,363.18
04/25/2025	25	4,750	14,915.00	23	4,000	12,720.00
04/28/2025	6	1,400	4,438.00	21	3,249	10,429.29
04/29/2025	-	-	-	5	750	2,445.00
04/30/2025	16	2,250	7,222.50	-	-	-
05/02/2025	1	340	1,098.20	7	540	1,760.40
05/05/2025	18	2,791	8,959.11	19	2,595	8,381.85
05/06/2025	10	1,574	5,021.06	20	2,485	8,001.70
05/07/2025	22	3,396	10,901.16	11	1,125	3,633.75
05/08/2025	42	5,091	16,138.47	-	-	-
05/09/2025	17	2,434	7,594.08	21	3,500	11,060.00
05/12/2025	28	4,080	13,015.20	24	4,055	13,016.55
05/13/2025	24	4,603	14,867.69	42	6,710	21,807.50
05/14/2025	31	5,018	16,007.42	6	1,241	4,008.43
05/15/2025	75	11,413	34,124.87	-	-	-
05/16/2025	37	6,597	18,735.48	19	3,002	8,645.76
05/19/2025	34	7,250	20,300.00	23	3,800	10,754.00
05/20/2025	18	3,500	9,835.00	28	5,095	14,469.80
05/21/2025	31	4,251	11,902.80	5	661	1,864.02
05/22/2025	9	2,119	5,848.44	16	2,813	7,848.27
05/23/2025	16	3,130	8,638.80	6	1,277	3,550.06
05/26/2025	-	-	-	21	3,304	9,317.28
05/27/2025	16	3,000	8,580.00	31	5,500	15,950.00
05/28/2025	12	1,750	5,110.00	5	472	1,387.68
05/29/2025	-	-	-	19	2,928	8,637.60
05/30/2025	14	2,658	7,761.36	5	768	2,265.60
06/02/2025	8	592	1,699.04	5	750	2,190.00
06/03/2025	5	900	2,592.00	35	7,032	21,025.68
06/04/2025	17	3,002	8,765.84	8	1,391	4,200.82
06/05/2025	18	3,167	9,152.63	20	3,001	8,762.92
06/06/2025	5	1,068	3,139.92	51	6,609	19,694.82
06/09/2025	16	2,811	8,376.78	16	2,750	8,277.50
06/10/2025	14	1,939	5,758.83	6	728	2,162.16
06/11/2025	12	2,495	7,335.30	-	-	-
06/12/2025	30	3,687	10,729.17	6	1,200	3,516.00
06/13/2025	11	1,726	4,970.88	15	2,250	6,547.50

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	1 886	322 578	1 074 534,26	1 610	276 147	938 985,90
06/16/2025	12	2,155	6,184.85	3	135	388.80
06/17/2025	16	1,975	5,549.75	7	1,250	3,537.50
06/18/2025	9	1,525	4,254.75	11	1,115	3,188.90
06/19/2025	4	1,000	2,840.00	-	-	-
06/20/2025	8	2,790	7,867.80	-	-	-
06/23/2025	57	6,867	18,678.24	1	1	2.73
06/24/2025	12	1,132	3,079.04	3	260	709.80
06/25/2025	38	5,311	14,286.59	6	1,241	3,449.98
06/26/2025	19	2,921	7,740.65	9	1,629	4,349.43
06/27/2025	18	3,117	8,197.71	6	466	1,234.90
06/30/2025	18	3,250	8,612.50	15	2,369	6,396.30

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <http://www.inventivapharma.com>

Contacts

Inventiva

Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937

ICR Healthcare

Media relations
Alexis Feinberg
inventivapr@icrhealthcare.com
+1 203 939 2225

Westwicke, an ICR Company

Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts

and estimates with respect to Inventiva's cash resources and expenses, including expectations and assumptions in connection with Inventiva's estimated cash runway, Inventiva's ability to raise additional funds, the implementation of the pipeline prioritization plan and related workforce reduction, and the timing thereof forecasts and estimates with respect to Inventiva's NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH, including design, duration, timing, costs, timing and the impact of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on the result thereof, and regulatory matters with respect thereto, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of lanifibranor, potential regulatory submissions, approvals and commercialization, and Inventiva's pipeline development plans, future activities, expectations, plans, growth and prospects. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", "designed", "hopefully", "target", "potential", "possible", "aim", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including the completion of financial closing procedures, that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the SUSAR on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including the timing, potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable

regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil, and natural catastrophes, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2024 filed with the Autorité des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption "Risk Factors" and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.